Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gdynia – page 8

232 clinical trials in Gdynia, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdynia at a glance
232
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

232 trials in Gdynia

Open in trial search

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Escherichia infection

Not recruiting

Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

Registered drug
Countries:PolandPoland
  • Participants:65+ years · Healthy volunteers
  • Substances:ECOO15
  • Sponsor:Janssen Vaccines & Prevention B.V.

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium chloride solution 0.9%
  • Sponsor:Pfizer Inc.

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Osteoporosis postmenopausal

Not recruiting

Study on the Effects of AGA2118 for Postmenopausal Women with Osteoporosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AGA2118
  • Sponsor:Angitia Inc. Ltd.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gdynia

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory viral infections, particularly evaluating new vaccines for elderly populations. Studies target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

  • Vaccine development for RSV
  • Prevention of respiratory infections
  • Immune response studies
02 Autoimmune Conditions

Comprehensive research into treatments for various autoimmune disorders, including psoriatic arthritis and plaque psoriasis. Studies evaluate novel therapeutics like zasocitinib and tildrakizumab.

  • Psoriasis management
  • Inflammatory bowel disease treatments
  • Arthritis therapies
03 Cardiovascular Research

Innovative trials investigating treatments for heart failure prevention and cardiovascular disease. Studies examine combination therapies and novel compounds for improving cardiac outcomes.

  • Heart failure prevention
  • Cardiovascular risk reduction
  • Combination therapy evaluation
04 Oncology Studies

Advanced research in breast cancer and prostate cancer treatments, focusing on metastatic disease and novel therapeutic combinations.

  • Metastatic breast cancer therapy
  • Prostate cancer treatment
  • Combination therapy approaches
Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.